Premium
Proteomic expression profiling of thyroid neoplasms
Author(s) -
Braunschweig Till,
Kaserer Klaus,
Chung JoonYong,
Bilke Sven,
Krizman David,
Knezevic Vladimir,
Hewitt Stephen M.
Publication year - 2007
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.200600381
Subject(s) - computational biology , gene expression profiling , profiling (computer programming) , thyroid , protein expression , biology , cancer research , computer science , gene expression , genetics , gene , operating system
Thyroid cancer is the most common endocrine neoplasm with multiple histologic subtypes, each associated with different treatments and outcomes. Differentiating benign neoplasms such as follicular adenomas from malignant entities such as follicular carcinomas and papillary carcinoma can be challenging. To define the proteomic profile of different thyroid tumors, we screened an antibody array of 330 features against five thyroid neoplasms: follicular adenoma, follicular carcinoma, papillary carcinoma, anaplastic carcinoma, and medullary carcinoma as well as normal thyroid epithelium. Eight candidate biomarkers; c‐erbB‐2, Stat5a, Annexin IV, IL‐11, RARα, FGF7, Caspase 9, and phospho‐c‐myc were identified as differentially expressed on the antibody array, and validated with immunohistochemistry on tissue microarrays, with a total of 144 samples of the same variety of thyroid neoplasms. Analysis revealed c‐erbB‐2, Annexin IV, and Stat5a have potential clinical utility to differentiate follicular adenoma, follicular carcinoma, and papillary carcinoma from each other. By using an antibody array as a discovery platform and a tissue microarray as a first step in validation on a large number of specimens, we have identified new markers that have potential utility in the diagnosis of thyroid neoplasms.